COVID-19 epidemiology (based on research to 21 February 2020)
Citation: Park M, Cook A, Lim J, et al. A systematic review of COVID-19 epidemiology based on current evidence. Journal of Clinical Medicine 2020; 9(4): 967
What is this? Information on the epidemiological characteristics of the coronavirus, SARS-CoV-2, and the effects of control measures can help policymakers and others involved in the management of the COVID-19 pandemic.
What was found: At the time of the review, available research showed that SARS-CoV-2 had an incubation period of 4 to 6 days, with 1.9 to 6.5 secondary cases generated by an infected patient, 5 to 8 days between successive infections and a doubling of the epidemic every 3 to 7 days.
At the time of the review, available research showed that age, gender and race did not affect a person’s susceptibility to the virus and the probability of transmission following contact with a COVID-19 patient.
At the time of the review, available research showed that the reported case fatality risk was 2% to 15%, highest in patients from older age groups and those with pre-existing conditions; and that children developed milder symptoms and had better prognoses.
At the time of the review, the estimated worldwide case fatality ratio was 0.3% to 1.4%, with 17.9% of infected cases being asymptomatic.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone. The text can be shared and re-used without charge, citing Evidence Aid as the source and noting the date on which you took the text.
We’ve already reached tens of thousands of people with plain language summaries of systematic reviews. If you’d like to help us to continue our work, please consider a donation.
Donate with PayPal
You can also donate through the Charities Aid Foundation (CAF) here. If you are based in the USA and want to make a tax-deductable donation, please donate to Evidence Aid via the British Schools and Universities Foundation.